AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30447891
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate 524 mg administered 30 min before DMF
Trial: 27753427
Drug: Video chat
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Video chat monitoring for pill-taking adherence
Trial: 26516614
Drug: l-dopa (Levodopa)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: l-dopa (Levodopa) administered preoperatively
Trial: 2050169
Drug: Both antidepressants
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antidepressants (amitriptyline and imipramine)
Trial: 6364591
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) ointment (200 mg applied three times a day for 3 weeks)
Trial: 14994322
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean daily dose 439.5 mg, range 150-750 mg)
Trial: 14994322
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean daily dose 438.5 mg, range 150-750 mg)
Trial: 22348468
Drug: DHA-enriched fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched fish oil supplement
Trial: 30195244
Drug: Grilled fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grilled fish (100 g per day)
Trial: 28712537
Drug: Bilateral, subretinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral, subretinal injection of 1·5×10^11 vector genomes of voretigene neparvovec in 0·3 mL total volume
Trial: 28712537
Drug: Bilateral, subretinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral, subretinal injection of voretigene neparvovec
Trial: 24821885
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab (1,400 mg)
Trial: 19182179
Drug: Risperidone 1.5-6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1.5-6.0 mg/day (regimen A)
Trial: 19182179
Drug: Risperidone 0.15-0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 0.15-0.6 mg/day (regimen B)
Trial: 8541533
Drug: 1,000 U
RxNorm normalized name: vitamin E 1,000 unit ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 U rHuEpo daily subcutaneously for 8 weeks
Trial: 8541533
Drug: 2,000 U
RxNorm normalized name: AHF 2,000 UNIT/VWF 800 UNIT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 U rHuEpo daily subcutaneously for 8 weeks
Trial: 8541533
Drug: 5,000 U
RxNorm normalized name: Decara 25,000 UNT Vegicaps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 U rHuEpo daily subcutaneously for 8 weeks
Trial: 8541533
Drug: 10,000 U
RxNorm normalized name: Erwinaze 10,000 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 U rHuEpo daily subcutaneously for 8 weeks
Trial: 2136809
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg toremifene
Trial: 16890670
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg toremifene
Trial: 16890670
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg toremifene
Trial: 31770513
Drug: CsA CE
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA CE low-dose (0.1% eye drops, twice daily + vehicle twice daily)
Trial: 26363701
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) plus standard care (medication and contact with the local clinical team)
Trial: 24548978
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation of lenvatinib (10 mg)
Trial: 24548978
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal with capsule formulation of lenvatinib (10 mg)
Trial: 24548978
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of lenvatinib (10 mg)
Trial: 7859889
Drug: Mean total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean total urinary iodine excretion (UIT)
Trial: 30974479
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy and Exercise (MT-EX)
Trial: 21446235
Drug: Hood nebulization
RxNorm normalized name: HOODIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hood nebulization of 0.30 mg/kg salbutamol
Trial: 21446235
Drug: Mask nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mask nebulization of 0.30 mg/kg salbutamol
Trial: 12768947
Drug: 2-weekly intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-weekly intramuscular penicillin
Trial: 9740926
Drug: Brompheniramine 12
RxNorm normalized name: BROMPHENIRAMINE 12MG/PSEUDOEPHEDRINE 120MG CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brompheniramine 12 mg
Trial: 6137325
Drug: Clopamide, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide, 5 mg/day
Trial: 6137325
Drug: Indapamide, 2.5
RxNorm normalized name: Indapamide, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide, 2.5 mg/day
Trial: 6137325
Drug: Chlorthalidone, 100
RxNorm normalized name: Chlorthalidone, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone, 100 mg/day + beta-blocker (propranolol or atenolol)
Trial: 6137325
Drug: Clopamide +
RxNorm normalized name: clopamide
DrugBank: Clopamide (DB13792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide + beta-blocker (pindolol, 10 mg/day)
Trial: 11220982
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg
Trial: 30261903
Drug: Sildenafil 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 75 mg
Trial: 30261903
Drug: Sildenafil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (3 times daily from 3 days before planned delivery until actual delivery)
Trial: 29603705
Drug: Articaine buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine buccal infiltration
Trial: 23054175
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment (CBT) added to managed care
Trial: 8454328
Drug: CMR vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR vaccine 60 micrograms
Trial: 8454328
Drug: CMR vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR vaccine 120 micrograms
Trial: 8454328
Drug: CMR vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR vaccine 30 micrograms
Trial: 16317122
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol from 3 large eggs (EGG) daily
Trial: 10804324
Drug: Apo(a) phenotypes
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apo(a) phenotypes determined using 4‐15% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting
Trial: 6341843
Drug: Standard (control)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (control) therapy
Trial: 24811601
Drug: PRT-201 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT-201 (high dose)
Trial: 24811601
Drug: PRT-201 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT-201 (low dose)
Trial: 1617983
Drug: N-acetylcysteine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 150 mg/kg as a loading dose and then 20 mg/kg/hr for 6 days
Trial: 27336868
Drug: Lornoxicam with
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam with 5 mg droperidol
Trial: 27336868
Drug: Lornoxicam with
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam with 8 mg ondansetron
Trial: 27336868
Drug: Lornoxicam with
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam with 6 mg granisetron
Trial: 23015161
Drug: Warfarin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosing algorithm
Trial: 20460558
Drug: Beers criteria
RxNorm normalized name: BEER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beers criteria drug
Trial: 2679331
Drug: Intrathecal diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal diamorphine 0.25 mg
Trial: 68703
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal spray
Trial: 68703
Drug: Oral syrup
RxNorm normalized name: Cola Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral syrup formulations
Trial: 19863501
Drug: Prednisolone (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (initial dose 0.5‐0.8 mg kg(‐1) daily for 2 weeks followed by placebo for 4 weeks)
Trial: 19863501
Drug: Ciclosporin (2.7‐4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (2.7‐4.0 mg kg(‐1) daily for 6 weeks)
Trial: 1671113
Drug: nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 10 mg with grapefruit juice
Trial: 1671113
Drug: nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 10 mg with water
Trial: 1671113
Drug: felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine 5 mg with orange juice
Trial: 31691521
Drug: Fast-Track Treatment
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-Track Treatment Initiation Counselling (FTIC)
Trial: 23600368
Drug: Highest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dose of rosuvastatin (40 mg/day)
Trial: 24618208
Drug: Add-on-statin extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks)
Trial: 1950641
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered (DesGly9‐Arg8) vasopressin (DGAVP)
Trial: 7028050
Drug: Ciclopiroxolamine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopiroxolamine cream (1% concentration) applied for 21 days
Trial: 7028050
Drug: Vehicle (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo cream) applied for 21 days
Trial: 29722071
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages with patient education material and treatment reminders
Trial: 21239069
Drug: losartan (weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan (weight-adjusted treatment)
Trial: 18675344
Drug: Griseofulvin lyophilized
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin lyophilized dry emulsion (LDE) tablet (125 mg) without water
Trial: 18675344
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) tablet
Trial: 15982992
Drug: alpha-lactalbumin protein
RxNorm normalized name: alpha-lactalbumin (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lactalbumin protein administration
Trial: 1669137
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of streptokinase (250,000 IU initial dose, 100,000 IU/h maintenance)
Trial: 1669137
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of streptokinase (500,000 IU initial dose, 250,000 IU every 12 h)
Trial: 1669137
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of streptokinase
Trial: 1669137
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of streptokinase
Trial: 6120902
Drug: 0.1 g
RxNorm normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g atenolol
Trial: 27888045
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg single dose)
Trial: 23292159
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nebulized inhalative epinephrine
Trial: 23292159
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg nebulized inhalative epinephrine
Trial: 23292159
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intramuscular epinephrine
Trial: 11099872
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg per day
Trial: 1059540
Drug: 9% stannous-fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9% stannous-fluoride treatment on right incisors before extraction
Trial: 31130270
Drug: Buteyko breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buteyko breathing technique in conjunction with medical management (nasal steroid)
Trial: 11029565
Drug: Lidocaine inhalation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inhalation (1%, 4%, and 10% concentrations, total doses of 0.5, 2.0, and 5.0 mg kg‐1)
Trial: 11029565
Drug: Lidocaine inhalation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inhalation (1%, 4%, and 10% concentrations)
Trial: 11029565
Drug: Lidocaine inhalation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inhalation (4% and 10% concentrations)
Trial: 11029565
Drug: Lidocaine inhalation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inhalation (4% solution)
Trial: 30463813
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg atorvastatin
Trial: 15167308
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein with 96 mg isoflavones/day
Trial: 15167308
Drug: Soy with
RxNorm normalized name: pediatric nutrition, soy with iron, lactose free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy with 52 mg isoflavones/day
Trial: 15167308
Drug: Soy without
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy without isoflavones (< 4 mg isoflavones/day)
Trial: 9679792
Drug: Minidose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minidose warfarin (1.25 mg/d)
Trial: 9679792
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus aspirin (1.25 mg/d + 300 mg/d)
Trial: 10068745
Drug: bismuth‐metronidazole‐amoxicillin‐ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bismuth‐metronidazole‐amoxicillin‐ranitidine
Trial: 2652906
Drug: Nisoldipine (calcium-channel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (calcium-channel blocker)
Trial: 319713
Drug: Oral atropine
RxNorm normalized name: atropine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atropine sulfate 0.5 mg four times a day
Trial: 25416496
Drug: Cuscuta planiflora
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuscuta planiflora capsules (500 mg) and conventional drugs
Trial: 25416496
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs only
Trial: 20516268
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU vitamin D(3) daily for 6 months
Trial: 20516268
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg elemental calcium daily for 6 months
Trial: 8580278
Drug: Budesonide enema
RxNorm normalized name: budesonide Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide enema (2 mg/100 mL)
Trial: 9348757
Drug: Psychoactive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoactive drugs (e.g., benzodiazepines)
Trial: 8281985
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg acetylsalicylic acid (ASA) infused intravenously
Trial: 8281985
Drug: ASA infusion
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA infusion
Trial: 24665827
Drug: PF4/H antibody-positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF4/H antibody-positive patients
Trial: 18356758
Drug: Family-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive-behavioral therapy (CBT)
Trial: 16008322
Drug: Prostina (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostina (2 capsules twice daily for 12 weeks)
Trial: 16008322
Drug: Terazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (2 mg at bedtime for 12 weeks)
Trial: 12466730
Drug: Hydralazine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine bolus injection (n = 44)
Trial: 10367320
Drug: Avonex 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avonex 6.0 MUI (30 micrograms) administered by intramuscular injection weekly
Trial: 7747534
Drug: Miconazole-hydrocortisone cream
RxNorm normalized name: hydrocortisone / miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole-hydrocortisone cream and ketoconazole shampoo (Group A)
Trial: 7747534
Drug: Hydrocortisone cream
RxNorm normalized name: Hydrocortisone Cream
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone cream and placebo shampoo (Group B)
Trial: 2157982
Drug: 33B3.1 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33B3.1 (10 mg per day)
Trial: 393377
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment only (control group)
Trial: 30660472
Drug: Clinical risk
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical risk model (Karnofsky performance status, radiation therapy)
Trial: 25992877
Drug: Tight intraoperative
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight intraoperative glucose control with hyperinsulinemic-normoglycemic clamp (target blood glucose, 80 to 110 mg/dl)
Trial: 23351820
Drug: Synchronous clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronous clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)
Trial: 11093435
Drug: Intramuscular methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular methotrexate (MTX)
Trial: 3495259
Drug: Domperidone 30
RxNorm normalized name: domperidone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 30 mg (D)
Trial: 20226302
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg, 10 mg, 20 mg
Trial: 20226302
Drug: Levocetirizine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 20 mg
Trial: 20226302
Drug: Desloratadine 20
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine 20 mg
Trial: 20226302
Drug: Increasing antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing antihistamine doses
Trial: 19083400
Drug: Hydrogen-rich water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich water (900 mL/d for 8 weeks)
Trial: 19083400
Drug: Placebo pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pure water (900 mL/d for 8 weeks)
Trial: 16650535
Drug: Endoscopic combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic combination therapy (n = 52)
Trial: 10772522
Drug: Blunt dilator/cannula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blunt dilator/cannula treatment
Trial: 1334825
Drug: 125I‐labeled soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I‐labeled soluble insulin
Trial: 31607641
Drug: Second-line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line chemotherapy (overall)
Trial: 28387882
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle preparation)